POPMIX 疑似哮喘患者人群医学多病共管干预:整群随机对照试验方案
本研究为在贵州省习水县开展的两臂、基于人群的分层整群随机对照试验,评估人群医学多病共管干预包对疑似哮喘患者的有效性。干预整合社区筛查、慢病管理、患者教育、数字随访和团队照护,覆盖26个乡镇、30余万常住居民。主要结局包括控制慢病数量、是否接受肺功能检测及ACT评分,并评估42项次要结局。
要点
- 在低资源山区县以乡镇为整群单位,分层随机开展人群医学多病共管干预。
- 干预包整合社区筛查、慢病管理、患者教育、数字随访与团队照护。
- 主要结局为控制慢病数量、肺功能检测接受情况及ACT评分。
核心结论
- 该整群随机对照试验旨在评估人群医学多病共管干预包对疑似哮喘患者的有效性。
- 试验结果将为全球卫生机构和从业者开展下一代多病共管与人群医学实践提供依据。
研究设计与样本
- 两臂、基于人群的分层整群随机对照试验,在贵州省习水县26个乡镇开展,覆盖30余万常住居民。
- 以乡镇为整群,按人口规模是否高于平均水平分为大乡镇和小乡镇两层,每层随机分配同等数量的居民接受ECRHS筛查。
- 筛查识别的疑似哮喘患者入组后分入干预组或对照组,干预组随访一年。
主要发现
- 干预组在3个月接受一次电话随访,并在6个月和12个月接受面对面随访;对照组仅在基线和12个月随访。
- 主要结局包括控制慢病数量、是否接受肺功能检测及ACT评分。
- 另评估42项次要结局,涵盖肺功能等生理功能指标、健康相关生活质量、心理健康、行为危险因素、卫生服务利用、生产力损失、哮喘与COPD知识及照护 cascade 指标。
关键数值与推荐
- 采用欧洲社区呼吸健康调查(ECRHS)识别疑似哮喘患者。
- 主要结局为控制慢病数量、是否接受肺功能检测及ACT评分。
临床怎么用
- 通过症状筛查识别未诊断哮喘患者并转诊至上级医院进行正式诊断和治疗。
- 以人群医学原则提供整体照护,提升疑似哮喘患者整体健康状况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Asthma is a common chronic disease responsible for a considerable disease burden in China and around the world. Despite its burden, there is substantial unmet need for asthma care, including screening, diagnosis, treatment, and management. Symptom-based screening for asthma could support identification of undiagnosed asthma patients, as well as reference to higher-level hospitals for formal diagnoses and treatment. This study focuses on identifying suspected asthma patients and encouraging them to seek formal diagnoses and treatment. This approach aligns with the novel concept of population medicine, which aims to maximize overall population health rather than focusing on individual patients within the health system. METHODS: We are conducting a two-arm population-based stratified clustered randomized controlled trial (cRCT) to evaluate the effectiveness of a population medicine multimorbidity intervention package. The intervention integrates community screening, chronic disease management, patient education, digital follow-up, and team-based care. The trial is being implemented in Xishui County, Guizhou Province, a mountainous low-resource county in Southwestern China, covering 26 townships and more than 300,000 permanent residents. We considered each of the 26 townships in Xishui County as a cluster and stratified them into large and small townships based on population size. Townships with an above-average population were designated as "large," and those with a below-average population were designated as "small." We randomized the same number of residents in each township stratum (large and small) to undergo the European Community Respiratory Health Survey (ECRHS) for identifying suspected asthma patients. Individuals identified as suspected asthma patients were considered study participants and subsequently enrolled in the intervention or control arm. All participants in the intervention arm are followed for one year, with one telephone follow-up at month three and in-person follow-ups at months six and 12, while participants in the control arm are followed only at baseline and 12 months. Primary outcomes include the number of chronic conditions controlled, whether the participant received lung function testing, and Asthma Control Test (ACT) score. In addition, we are evaluating 42 secondary outcomes covering physiological and functional indicators such as lung function, health-related quality of life, mental health, behavioral risk factors, healthcare utilization, productivity loss, knowledge of asthma and chronic obstructive pulmonary disease (COPD), and care cascade indicators for asthma and other chronic diseases. DISCUSSION: This cRCT has been featured as an important case study in the Lancet Commission on Investing in Health report to evaluate the effectiveness of the integrated intervention package on priority conditions. The trial was designed under population medicine principles, with an aim providing holistic care and enhancing the overall health status of suspected asthma patients. The results of the trial will inform the next generation of multimorbidity management and population medicine practices among global health authorities and practitioners. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06457009. Registered on June 7, 2024.
引用
- Huang K, Tong X, Tang X, et al. Impact of the POPulation Medicine Multimorbidity Intervention in Xishui County (POPMIX) on suspected asthma patients: protocol for the POPMIX-Asthma cluster-randomized controlled trial. Trials. 2026. PMID: 41964072. doi:10.1186/s13063-026-09685-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。